News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Proteome Sciences PLC H1 Pretax Loss Narrows; Sees Licensing for TMT by Year-End
October 2, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - Proteome Sciences PLC posted a narrower first half pretax loss and higher revenues and said it is "well set" to provide strong and sustainable revenue stream.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Layoff Tracker
Takeda Restructuring Will Affect Workforce, Could Include Layoffs
March 26, 2026
·
40 min read
·
BioSpace Editorial Staff
Weight Loss
Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs
March 25, 2026
·
3 min read
·
Heather McKenzie
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
March 25, 2026
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms
March 25, 2026
·
3 min read
·
Tristan Manalac
